Bringing cheap and accurate tuberculosis tests to Africa

January 17, 2018 by Silke Schmidt, University of Wisconsin-Madison
For a previous project also funded by the Gates Foundation, Salus Discovery researchers provide training to Uganda-based staff on a new diagnostic test for HIV/AIDS. Field training for the new tuberculosis test will begin in spring 2018 in Ethiopia and South Africa. Credit: Salus Discovery

Since the 1970s, millions of women have appreciated the ease of a urine-based home pregnancy test to find out if their family is about to grow.

A diagnostic test that's just as accurate and easy to use would make a big impact in the war on tuberculosis (TB). With more than 10 million affected people worldwide, many of them in Africa, the annual market for such a test is estimated at about 75 million—but only if it costs as little as $2 apiece.

David Beebe and his colleagues think they can deliver on that.

"We've come up with a robust, simple and inexpensive way to increase the sensitivity of an existing TB test by integrating a concentration enrichment step into a protocol that's very similar to the familiar pregnancy test," says Beebe, a biomedical engineering professor at the University of Wisconsin–Madison. "And we think this new technology may soon not only detect TB in urine, but also diagnose many other conditions in both the developing and developed world."

Researchers with Beebe's spinoff company Salus Discovery, founded in 2013, completed much of the intellectual work behind the new technology in 2017 thanks to a recently awarded $2.6 million grant from the Bill and Melinda Gates Foundation. The grant funds the TB project until fall 2019, and includes eight subcontracts to private companies and other organizations in six countries.

Among these is TBDiadirect AB, a Swedish company that has developed antibodies for the lipoarabinomannan (LAM) protein in urine and enabled its use as a biomarker for active TB; and the British company Mologic, which put urine-based pregnancy tests on the mass market more than 30 years ago. A Gates Foundation program officer connected Beebe with the European researchers and had enough confidence in their ability to deliver the desired TB test that the project was funded without a detailed outline of how exactly they would get to that goal.

"Not being constrained by preconceptions and having more freedom to think outside the box than you typically do with traditional government grants has been great," Beebe says.

Most current TB tests are DNA-based, time-consuming and expensive—not to mention unpleasant, as they rely on a saliva-and-mucus sample coughed up from a person's respiratory tract. An additional limitation is that many tests only work in HIV-positive patients, who are at greater risk of developing TB.

"But that's a small percentage of all cases, and a broadly applicable triage test is urgently needed to start treatment as early as possible," Beebe explains.

The new is based on a proprietary and innovative sample preparation technology, and detects the LAM protein at much lower concentration than existing urine-based tests. The engineers who designed the test also accounted for the environmental conditions in which it might be used in Africa, such as dust, high humidity and hot temperatures, and for the country's limited clinical infrastructure.

Several Salus employees—all but one of whom are alumni of Beebe's UW–Madison lab—will visit their collaborators in Ethiopia and South Africa in the spring of 2018 to begin to validate the test on patient urine samples.

Beebe's next goals are to obtain World Health Organization certification for the new and help start a company in Africa to manufacture TB screening kits. Since Salus is a for-profit company with philanthropic tendencies, as Beebe likes to describe it, that approach will create jobs and provide a more sustainable solution than manufacturing the kits in the United States and then shipping them to where they are needed.

The long-term future includes broadening areas of application for tests of this kind.

"Assay sensitivity is a core issue within the molecular diagnostic community," says biomedical engineer John Guckenberger, one of the lead developers at Salus. "We believe that our assays can be applied to several other diseases, including HIV, flu, MRSA, pneumonia and hepatitis, just to name a few."

According to Beebe, this project and others are the culmination of his more than 10 years of experience working with African partner organizations.

"We're excited to lead an exceptionally talented group of international collaborators toward a goal that's incredibly important to global health and has the potential to save at least 400,000 lives a year," he says.

Explore further: Beebe vetoes bill to ban abortions at 12 weeks

Related Stories

Beebe vetoes bill to ban abortions at 12 weeks

March 4, 2013
(AP)—Arkansas Gov. Mike Beebe has vetoed legislation that would have banned abortions 12 weeks into a pregnancy.

Urine test developed to test for tuberculosis

December 14, 2017
(Medical Xpress)—An international team of researchers has developed a urine test that can be used to detect tuberculosis (TB) in human patients. In their paper published in Science Translational Medicine, the group describes ...

The key to easy asthma diagnosis is in the blood

April 15, 2014
Using just a single drop of blood, a team of University of Wisconsin-Madison researchers has developed a faster, cheaper and more accurate tool for diagnosing even mild cases of asthma.

New test aids personalized cancer care

June 12, 2015
In a highly successful, first-of-its-kind endeavor, a multidisciplinary team of University of Wisconsin-Madison researchers have created a "tumor in a dish:" an ex vivo microenvironment that can accurately anticipate a multiple ...

French scientists devise fast-track test for Ebola

October 21, 2014
A new device similar to a simple pregnancy home-test could allow doctors to diagnose a patient with suspected Ebola in under 15 minutes, its French developers said Tuesday.

Recommended for you

Dialysis patients at risk of progressive brain injury

December 10, 2018
Kidney dialysis can cause short-term 'cerebral stunning' and may be associated with progressive brain injury in those who receive the treatment for many years. For many patients with kidney failure awaiting a kidney transplant ...

PET scans to optimize tuberculosis meningitis treatments and personalize care, study finds

December 6, 2018
Although relatively rare in the United States, and accounting for fewer than 5 percent of tuberculosis cases worldwide, TB of the brain—or tuberculosis meningitis (TBM)—is often deadly, always hard to treat, and a particular ...

Silicosis is on the rise, but is there a therapeutic target?

December 6, 2018
Researchers from the CNRS, the University of Orléans, and the company Artimmune, in collaboration with Turkish clinicians from Atatürk University, have identified a key mechanism of lung inflammation induced by silica exposure, ...

Infectivity of different HIV-1 strains may depend on which cell receptors they target

December 6, 2018
Distinct HIV-1 strains may differ in the nature of the CCR5 molecules to which they bind, affecting which cells they can infect and their ability to enter cells, according to a study published December 6 in the open-access ...

Protecting cell powerhouse paves way to better treatment of acute kidney injury

December 6, 2018
For the first time, scientists have described the body's natural mechanism for temporarily protecting the powerhouses of kidney cells when injury or disease means they aren't getting enough blood or oxygen.

New study uncovers why Rift Valley fever is catastrophic to developing fetuses

December 5, 2018
Like Zika, infection with Rift Valley fever virus can go unnoticed during pregnancy, all the while doing irreparable—often lethal—harm to the fetus. The results of a new study, led by researchers at the University of ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.